French firm Defymed has developed a new insulin delivery device ExOlin to facilitate better disease management for both type 1 and type 2 diabetes patients.

ExOlin consists of a biocompatible membrane that is non-biodegradable and permeable to insulin.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The device is designed as an abdominal implant and allows delivery of insulin to a physiological site when injected through the skin, in contrast to other tools such as pens and external pumps involving subcutaneous delivery.

It is expected that the new delivery device will enable stabilisation of blood sugar levels in the long-term while allowing continuation of conventional injections methods.

Defymed CEO and founder Dr Séverine Sigrist said: “With ExOlin, Defymed shall offer diabetic patients a more physiological approach for delivering insulin. The therapeutic effectiveness of the treatment should thus be significantly improved.

"The patient should also benefit from greater stability in their blood sugar levels and therefore a better quality of life."

“The patient should also benefit from greater stability in their blood sugar levels and therefore a better quality of life.”

The firm intends to commence the clinical evaluation of ExOlin next year in eight European patients, with plans to commercialise the device in the country by the end of 2020 after obtaining CE Mark.

Defymed will later apply for an approval from the US Food and Drug Administration (FDA) and seeks to raise €10m to support the process of clinical development.

In addition to diabetes management, ExOlin has the potential to be adapted for other applications and pathologies that require a physiological method to deliver drugs or active ingredients.